Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of 8.77% and Operating profit at 11.60% over the last 5 years
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
PLN 33 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.03
-4.69%
0.69
Revenue and Profits:
Net Sales:
23 Million
(Quarterly Results - Mar 2025)
Net Profit:
1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.07%
0%
-24.07%
6 Months
-30.38%
0%
-30.38%
1 Year
-7.75%
0%
-7.75%
2 Years
-43.75%
0%
-43.75%
3 Years
-58.26%
0%
-58.26%
4 Years
-69.25%
0%
-69.25%
5 Years
-70.71%
0%
-70.71%
PZ Cormay SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.77%
EBIT Growth (5y)
11.60%
EBIT to Interest (avg)
-2.83
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.64
Tax Ratio
0.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.74
EV to EBIT
-15.99
EV to EBITDA
10.21
EV to Capital Employed
0.75
EV to Sales
0.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.67%
ROE (Latest)
-7.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
22.80
24.60
-7.32%
Operating Profit (PBDIT) excl Other Income
1.30
1.50
-13.33%
Interest
0.20
0.30
-33.33%
Exceptional Items
0.10
-0.10
200.00%
Consolidate Net Profit
0.60
-0.00
Operating Profit Margin (Excl OI)
-5.40%
-7.30%
0.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -7.32% vs 8.37% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 0.00% vs 100.00% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
91.60
82.20
11.44%
Operating Profit (PBDIT) excl Other Income
0.60
-0.60
200.00%
Interest
0.90
0.90
Exceptional Items
-1.10
3.00
-136.67%
Consolidate Net Profit
-5.30
-4.60
-15.22%
Operating Profit Margin (Excl OI)
-54.10%
-69.20%
1.51%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 11.44% vs -3.75% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -15.22% vs 34.29% in Dec 2023
About PZ Cormay SA 
PZ Cormay SA
Pharmaceuticals & Biotechnology
PZ Cormay SA is a Polish-based producer and wholesaler of diagnostic reagents and a distributor of the laboratory equipment. The Company is engaged in the design, manufacture and distribution of a range of products for clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation and specific protein recognition. It offers drugs, biochemical rapid tests and devices such as vacuettes and tubes. PZ Cormay SA provides also biochemical analyzers: ACCENT-300, ACCENT-200, PRESTIGE 24i and LIVIA; hematological analyzers: MYTHIC 18, among others, and urinalysis apparatus: IChem 100. On September 1, 2014, Orphee SA acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee SA.
Company Coordinates 
Company Details
Ul. Wiosenna 22 , LOMIANKI None : 05-092
Registrar Details






